EXCYTE (Beijing) Pharmaceutical Technology Development Co., Ltd.

EXCYTE (Beijing) Pharmaceutical Technology Development Co., Ltd.
  • Home
  • About Us
    全部 Introduction Team Corporate Honors History
  • Pipeline
  • Technology
  • News
  • Job
  • Contact

  1. Home
  2. News

Zhongguancun cutting-edge technology enterprise

2020-09-10 09:58:28 admin 22

It is not easy for 2020 to be a real mouse, and the world will change in 2021. With the footsteps of 2021 quietly coming, Ecotech has ushered in the first gold-lettered signboard of the new year - Zhongguancun cutting-edge technology enterprise.

益科思特(北京)科技医药科技发展有限公司官网


  • Previous : Top 50 of the "Maker Beijing 2020" epidemic prevention and control special competition
  • Next : In May 2020, the article on COVID-19 treatment antibody was published in Cold Spring Harbor of the United States
  • News

为你推荐

  • Innovative bispecific antibody YKST02 officially started Phase I clinical trial
  • First in human (FIH) dosing completed for YKST02, a bispecific antibody drug for multiple myeloma immunotherapy in Phase I clinical trial
  • The IND application for YKST02 has been approved, and Phase I clinical trials will start soon
  • The signing ceremony for the Phase Ib/II clinical study of YK012 in the treatment of ALL was successfully held
  • NHL/ALL Immunotherapy Candidate Double Antibody YK012 Phase I Clinical Trial Completed First Subject Administration

版权所有 2017-2026 京ICP备17063430号

5 Kaituo Road, Haidian District, Beijing (Zhongguancun Bio-medicine Park) Room B306-308

18910977588

Powered by  MetInfo  7.5.0